What's new

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one Treatment of pantothenate kinase-associated neurodegeneration, 19/07/2021 Withdrawn

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one Treatment of pantothenate kinase-associated neurodegeneration, 19/07/2021 Withdrawn

Jun 10, 2025 - 08:25
 0
Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one Treatment of pantothenate kinase-associated neurodegeneration, 19/07/2021 Withdrawn
Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one Treatment of pantothenate kinase-associated neurodegeneration, 19/07/2021 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropy...

Next Article

Orphan designation: nerandomilast Treatment of idiopathic pulmonary fibrosis, 28...

Related Posts

Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Date of authorisation: 02/02/2001, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0

European Medicines Agency decision CW/0001/2025 of 2 Ju...

Jun 3, 2025  0

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 13:50 (CEST)

EMA roundtable with stakeholders on the 20th anniversar...

Jun 4, 2025  0